Prexa Pulls In $7M From Advent, Shire

5/11/11Follow @xconomy

Prexa Pharmaceuticals, a Boston-based biotech developing experimental drugs for treating central nervous disorders, announced it wrapped up a $7 million Series B funding round from Advent Healthcare Ventures and new investor Shire Pharmaceuticals. Prexa, which previously raised $3.1 million in Series A money, was co-founded by Advent in 2006 and is working on molecules to safely enhance dopamine activity and norepinephrine activity, to improve on existing treatments for for ADHD, depression and Parkinson’s disease.